Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Drug Discovery
Overview
Conditions
Intellectual Property
Research
R&D Pipeline
Cobroxin
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Intellectual Property

Intellectual PropertyNutra Pharma seeks patent and other intellectual property rights to protect and preserve our proprietary technology and our right to capitalize on the results of our research and development activities. We also rely on trade secrets, know-how, continuing technological innovations and licensing opportunities to prove competitive advantages for our products in our markets and to develop new products.

Nutra Pharma holds a license to certain intellectual property from Bio Therapeutics, which it intends to utilize in conjunction with Receptopharm's research and development of modified venom and peptides thereof in applications for the treatment of HIV and MS.

Patents

  • U.S. Patent No. 5,989,857, which was granted in November 1999 with 10 claims.
  • U.S. Patent No. 6,670,148, which was granted in December 2003, with 9 claims. The patent further describes the method for preparing a bioactive peptide (protein) found in cobra venom, in a stable, inactivated form, by treating the peptide with ozone.
  • Buccal Delivery System, on which a patent is pending. This application describes a throat spray that permits efficient delivery of the modified peptide drugs to the body through oral mucosa.
  • Technology contained in one pending U.S. patent application for the further development of bioactive peptides in cobra venom for use in the treatment of HIV and MS.
  • Technology contained in two pending U.S. patent applications for Immunokine Composition and Method, which describes a method for developing modified peptides from alpha-cobratoxin.
  • Technology contained in two patents pending for the topical delivery of our proprietary wound healing treatment, which was developed in conjunction with Bio Therapeutics. One of these products is in the form of an ointment style skin protectant and the other a foaming aerosol.
 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
June 10, 2014
Nutra Pharma Announces Contracts for Nyloxin Television Commercials


January 07, 2014
Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs


December 02, 2013
Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics